Proactive Investors - Run By Investors For Investors

Collagen Solutions waiting on CE Mark for ChondroMimetic knee cartilage scaffold

Results from an eight-year clinical extension study showed that ChondroMimetic was able to regenerate cartilage to a structural quality almost identical to native cartilage
knee physio
The award of a CE Mark for ChondroMimetic could come as early as the end of March
  • Specialises in regenerative medicines and biomaterials

  • Makes everything from heart valves to wound dressings

  • Award of CE Mark for ChondroMimetic next major inflection point

  • Asian and European distribution agreements already in place

 

What it does

As it name suggests, Collagen Solutions PLC (LON:COS) specialises in making regenerative medicines and biomaterials.

It uses collagen and/ or tissue – such as pericardium – to make everything from heart valves to bone grafts right through to wound dressings. It all depends on what the customer wants.

Collagen has another string to its bow though, in the shape of its lead product called ChondroMimetic.

ChondroMimetic is a minimally-invasive surgically placed scaffold which helps to repair knee cartilage.

Last February, results from an eight-year clinical extension study showed that ChondroMimetic was able to regenerate cartilage to a structural quality almost identical to native cartilage.

 

How it’s doing

Work on a CE Mark, which would signify that the product has passed safety, health and environmental protection requirements, began almost straight after those results came in.

Collagen had hoped to hear whether or not it had been successful by the end of March 2019, although with the process out of its hands, it recently admitted that the timing of any award is “uncertain”.

Currently, ChondroMimetic is not approved for sale in any market, but Collagen has been working hard behind the scenes so that it is ready for sale as soon as the CE Mark is awarded.

Most recently, it signed a licence and distribution agreement with Rajawali Medika which it will work with to obtain regulatory approval and launch the cartilage scaffold in Indonesia. There is the potential for this deal to include several other countries in South East Asia as well.

That agreement adds to similar deals it has already secured elsewhere in Asia and in Europe.

 

Revenues rise in first half

Away from ChondroMimetic, Collagen saw demand for its products surge in the first half of its financial year.

The AIM company won nine new contracts in the six months ended September 30 (H1 17: eight) and began to supply to sixteen new customers (H1 17: eight).

That helped to push revenue up by 13% year-on-year to £2.10mln (H1 17: £1.86mln). When adjusted for the loss of a key Korean customer, who is not expected to order again until next year, revenue grew by 55%.

The new contracts were typically higher value than those that had been signed in the past as well, narrowing the half-year pre-tax loss to £1.06mln (H1 17: £1.64mln).

At the end of the period, Collagen had £2.56mln of cash in the bank, although in January it secured a £1.54mln grant from the Scottish government.

 

What the boss is saying

View full COS profile View Profile

Collagen Solutions PLC Timeline

Related Articles

human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
cancer
February 25 2019
Immunotherapy treatment Clevegen is on phase I/II trial (MATINS) for metastatic tumours
Scientists in a lab
January 31 2019
CEO Gary Phillips says Pharmaxis’ healthy cash balance gives it time to choose between in-house and partnering options.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use